Framingham-based Transport Pharmaceuticals reported positive results from its Phase I clinical trial of its drug SoloVir, which is being developed to treat cold sores.
The study included 32 volunteers and was the first clinical application of the company’s new SoloVir combination product. During the trial, subjects were given four treatments over the course of two days to assess the safety of the treatment, which is applied directly to the skin.
The company reported that the treatments were “well tolerated by all subjects, with no significant skin irritation and few, mild adverse events.”
SoloVir is poised to compete against GlaxoSmithKline’s Valtrex, which is an oral drug.
Transport plans to begin a double blind, placebo controlled Phase II trial of SoloVir in the second quarter of the year.
